Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate the Safety, Tolerability and Efficacy of CT-011 Administered Intravenously to Patients With Metastatic Melanoma

NCT01435369 is registered in ClinicalTrials.gov with Medivation, Inc. as lead sponsor.

NCT NCT01435369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01435369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate the Safety, Tolerability and Efficacy of CT-011 Administered Intravenously to Patients With Metastatic Melanoma
Lead sponsor
Medivation, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
August 31, 2013
Enrollment
103 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma, melanoma